I can't recall if this discussion was put to bed, but when talking about the M-Enoxaparin multiple generics scenario, Shea said something to the effect of "In the case of other interchangeable generics, Momenta would receive a high single or low double digit royalty".
In other words, the discussion of substitutible vs non-substituble Lovenox in the case of Teva and other competitors is very pertinent to Momenta's partnership agreement with Sandoz/Novartis.
News 
Market Data 
Discover 
